Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Crohn's Disease
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 109
States / cities: Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, IMGN632, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: Duarte, California • Orange, California • Tampa, Florida + 10 more

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Obesity, Pregnancy, Breastmilk Collection, Infant Overnutrition, Gestational Diabetes Mellitus (GDM)
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 45 Years
Enrollment: 2,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Oklahoma City, Oklahoma

Conditions: Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Interventions: MemoryShape® Breast Implants, MemoryGel® Breast Implants, Other Aesthetic Surgery; Device · Procedure
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3,603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 78
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more

Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Interventions: High-effort resistance exercise training, Low-effort resistance exercise training; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions: Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, Systemic Therapy; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 108
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 80 more

Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Enfortumab Vedotin, Erdafitinib, Multigated Acquisition Scan; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more

Conditions: Low Back Pain
Interventions: Intracept Procedure; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah

Conditions: Mental Disorder
Interventions: Enhancing Your Immune Health; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Stroke
Interventions: MARK; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lupus Erythematosus, Systemic
Interventions: Litifilimab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Glendale, Arizona • Huntington Beach, California + 38 more

Conditions: Glioblastoma, Glioblastoma, WHO Grade IV
Interventions: Temozolomide (TMZ), Optune System, Pembrolizumab; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Plantar Fascitis
Interventions: Radial shockwave therapy, Focused shockwave therapy, Shockwave therapy device, Home therapy; Procedure · Device · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 100 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: MSPA eClass; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Cardiovascular Disease
Interventions: Cardiac MRI; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2051
U.S. locations: 2
States / cities: Los Angeles, California • Gainesville, Florida

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: D-4517.2; Drug
Lead sponsor: Ashvattha Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Los Angeles, California • Lemont, Illinois • Indianapolis, Indiana + 12 more

Conditions: Hematologic Neoplasms
Interventions: Omission of the drug mycophenolate mofetil; Other
Lead sponsor: Ronald Paquette; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more

Conditions: Circadian Dysregulation
Interventions: Habit-based Sleep Health Intervention, Text messaging intervention; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 30 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Polymyalgia Rheumatica
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more

Conditions: Chronic Rhinitis
Interventions: NEUROMARK System; Device
Lead sponsor: Neurent Medical; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Roseville, California + 6 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Lunsekimig, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: La Jolla, California • Roseville, California • Boise, Idaho + 6 more

Search by objective public record fields.

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Maternal Obesity, Breast Milk Composition, and Infant Growth

Memory Gel and Shape Combined Cohort

Resistance Training for the Improvement of Glycemic Control in Prediabetes

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Intracept Intraosseous Basivertebral Nerve Ablation

Enhancing Immune Health Randomized Controlled Trial

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

EMG Controlled Device in Acute Rehabilitation After Acute Stroke

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

Shockwave Therapy for Plantar Fasciitis RCT

A Health Action Process Approach Online Intervention for People With Multiple Sclerosis

Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Maintaining Behavior Change: An Evaluation of a Habit-based Sleep Health Intervention

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NEUROMARK Registry Study

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study